article thumbnail

RCT of PC in ED: Corita Grudzen, Fernanda Bellolio, & Tammie Quest

GeriPal

It was really at the level of the ED across 33 EDs in random order, and then tried to see if we could make a difference in healthcare utilization, primarily the primary outcome was admission to the hospital, acute care admission. Yeah, that’s a more complicated story. But yeah, it’s complicated. Is that right?

article thumbnail

Private Equity Gobbling Up Hospices plus Hospice and Dementia: Melissa Aldridge, Krista Harrison, & Lauren Hunt

GeriPal

Eric: Whenever I hear about for-profit, non-for-profit, the differences between them, mostly everybody turns to, I think, your 2014 paper looking at the differences between for-profit and non-for-profit. It’s something we need to pay attention to, which is what we were talking about in the article. It waxes and it wanes.

Family 106
article thumbnail

Ding Dong is the Skinny Label (Effectively) Dead?

FDA Law

Briefly (more detail is available here ), GSK sued Teva back in 2014 alleging that Teva induced infringement of a method-of-use patent when Teva marketed a skinny-labeled generic version of GSK’s Coreg (carvedilol) as AB-rated. Especially now with the utility of the use code minimized. Teva decision changed everything.

IT 52